The impact of pre-transplant ventricular assist device support in pediatric patients with end-stage heart failure on the outcomes of heart transplantation—“a single center experien... by L. Lily Rosenthal, L. Lily Rosenthal, L. Lily Rosenthal, Carola Grinninger, Sarah Marie Ulrich, Robert Dalla Pozza, Nikolaus A. Haas, Paolo Brenner, Michael Schmoeckel, Sebastian Michel, Sebastian Michel, Sebastian Michel, Christian Hagl, Christian Hagl, Jürgen Hörer, Jürgen Hörer, Jürgen Hörer

“…Odds ratio [OR] is as follows: 1.992, 95% confidence interval [CI]: 0.983–1.007, p = 0.266, aortic clamp time per minutes: OR: 1.008, 95% CI: (0.997–1.019), p = 0.164, HLM time per minutes: OR: 0.996, 95% CI: (0.991–1.001), p = 0.146, Operation time per minutes: OR: 1.000, 95% CI: (0.995–1.004), p = 0.861.ConclusionThe provision of pre-HTx VAD support does not have an adverse effect on the short- and long-term survival of pediatric patients undergoing HTx. …”
Get full text

The in vivo metabolic pathway of Deg-AZM and in vitro investigations into the contribution of drug metabolizing enzymes and drug transporters in the drug interactions of Deg-AZM, a... by Xiaoting Gu, Xiaohe Li, Weixue Tian, Chaoyue Zheng, Chaoyue Zheng, Yutian Cai, Yutian Cai, Xiang Xu, Xiang Xu, Conglu Zhao, Conglu Zhao, Hongting Liu, Hongting Liu, Yao Sun, Yao Sun, Zhilin Luo, Zhilin Luo, Shuwen Zhu, Shuwen Zhu, Honggang Zhou, Honggang Zhou, Xiaoyu Ai, Cheng Yang, Cheng Yang

“…Human liver microsome phenotyping assays with chemical inhibition and recombinant CYPs phenotyping assays were used to investigate the CYP450 enzyme phenotype involved in Deg-AZM metabolism in vitro. A HLM inhibition reaction system was established to evaluate the inhibitory effect of Deg-AZM on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. …”
Get full text